Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05509257
Other study ID # STUDY00002228
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date September 17, 2022
Est. completion date June 2027

Study information

Verified date October 2023
Source Children's Mercy Hospital Kansas City
Contact John Tumberger, BS
Phone 8164829872
Email jtumberger@cmh.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).


Description:

The investigators will use a randomized, placebo-controlled, double-blind, crossover trial to evaluate the use of fMRI as a pharmacodynamic biomarker of reward system modulation. The overall goal of this work is to develop an objective tool to detect acute drug response. If validated in future, larger trials, the pharmacodynamic biomarker may facilitate early phase/quantitative pharmacology studies of novel or repurposed agents expected to modulate the reward system. The reward system will be antagonized by naltrexone in adolescents aged 13-21 years with an ED defined by binge/purge behaviors (e.g., Anorexia Nervosa-Binge Purge, Bulimia Nervosa, Binge Eating Disorder). A crossover design was chosen to quantify within-individual change in opioid reward pathway modulation following antagonism. Eligible patients will be randomly assigned to Group A or Group B. A statistician (or other non-study staff) will generate the schedule and communicate with the investigation drug service to maintain the double-blind design. A washout period of at least 14 days will exceed the 48-hour carry-over effect from naltrexone 50 mg administered orally. The two study visits will be mirrored in structure and duration to maintain blinding. It is not the intent of this study to generate data for submission to the FDA or to support a significant change in advertising of the drug. Storage, control and dispensation of the drug will occur through collaboration with the investigational drug service (IDS) pharmacy. Use of naltrexone for this study meets criteria for investigational new drug (IND) exemption, category #1 (21 Code of Federal Regulations (CFR) 312.2(b)(1)).


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 13 Years to 21 Years
Eligibility Inclusion Criteria: - Adolescents and young adults aged 13-21 years - Eating disorder diagnosis characterized by binge eating and/or purging (eg, Anorexia Nervosa-Binge/Purge, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding/Eating Disorder) using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria. - Stable medication regimen (no dose or drug changes in the past 4 weeks) - Participant and parent/legal guardian (if under 18 years) are willing and able to provide informed permission/assent/consent for the study Exclusion Criteria: - Pregnant (via UCG) - Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis) - Non-removable metal in the body that is magnetic resonance imaging incompatible - Current naltrexone use - Self-reported opioid use in the past 7 days - A language barrier (e.g., non-English speaking) for the participant that precludes communication and/or ability to complete all study-related requirements.

Study Design


Intervention

Drug:
Naltrexone
Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
Placebo
Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.

Locations

Country Name City State
United States Children's Mercy Research Institute Kansas City Missouri

Sponsors (2)

Lead Sponsor Collaborator
Children's Mercy Hospital Kansas City University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Acute %Blood oxygenation level dependent (BOLD) change placebo vs. naltrexone in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex) 2 hours post medication (naltrexone or placebo)
Secondary Maximum Concentration in Plasma (Cmax) Naltrexone systemic exposure defined by the pharmacokinetic parameter Cmax Blood sampled 0-7 hours post medication
Secondary Area Under the Plasma Concentration vs. Time Curve (AUC) Naltrexone systemic exposure defined by the pharmacokinetic parameter AUC Blood sampled 0-7 hours post medication
See also
  Status Clinical Trial Phase
Recruiting NCT05656859 - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT03050632 - Effects of Cognitive and Emotional Functioning on Treatment Outcomes N/A
Completed NCT02484794 - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application N/A
Completed NCT02567890 - Swedish Body Project for Prevention of Eating Disorders N/A
Completed NCT02252822 - Improving Treatment Engagement for Adolescents With Bulimia Nervosa N/A
Completed NCT02021344 - Mental Health First Aid for College Students N/A
Completed NCT00601354 - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder N/A
Completed NCT00418977 - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Completed NCT00733525 - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa N/A
Active, not recruiting NCT04779216 - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Phase 3
Completed NCT04433663 - Eating Disorders, Self Regulation and Mentalization N/A
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT05730348 - Mealtime Anxiety in Eating Disorders
Enrolling by invitation NCT05814653 - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders N/A
Completed NCT04506216 - Eating Disorders in Type 1 Insulin-dependent Diabetes Patients N/A